factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fact | preserve | 3585-3599 | 3594-3599 | T238 | axillary nodes | LOCATION_OF | 3,585 | 3,599 | preserve | 3585-3593 | 3585-3593 | T227 | axillary | BodyLocationOrRegion | 3,585 | 3,593 | preserve | 3594-3599 | 3594-3599 | T228 | nodes | BodyPartOrganOrOrganComponent | 3,594 | 3,599 | A16 | Low levels of VEGF and the presence of less than three involved axillary nodes characterize the patients with NPBC treated with adjuvant tamoxifen who have the highest likelihood of favorable outcome. | 3521-3734 | 3,521 | 3,734 | Low levels of VEGF and the presence of less than three involved @SUBJECT$ @PREDICAT$ @OBJECT$ characterize the patients with NPBC treated with adjuvant tamoxifen who have the highest likelihood of favorable outcome. |
Fact | preserve | 3632-3636 | 3632-3636 | T239 | with | PROCESS_OF | 3,632 | 3,636 | preserve | 3637-3641 | 3637-3641 | T231 | NPBC | NeoplasticProcess | 3,637 | 3,641 | preserve | 3623-3631 | 3623-3631 | T229 | patients | PatientOrDisabledGroup | 3,623 | 3,631 | A18 | Low levels of VEGF and the presence of less than three involved axillary nodes characterize the patients with NPBC treated with adjuvant tamoxifen who have the highest likelihood of favorable outcome. | 3521-3734 | 3,521 | 3,734 | Low levels of VEGF and the presence of less than three involved axillary nodes characterize the @OBJECT$ @PREDICAT$ @SUBJECT$ treated with adjuvant tamoxifen who have the highest likelihood of favorable outcome. |
Uncommitted | preserve | 1060-1062 | 1060-1062 | T76 | in | ASSOCIATED_WITH | 1,060 | 1,062 | preserve | 1041-1043 | 1041-1043 | T72 | TP | AminoAcidPeptideOrProtein | 1,041 | 1,043 | preserve | 1067-1080 | 1075-1080 | T73 | primary tumor | NeoplasticProcess | 1,067 | 1,080 | A20 | The cytosolic levels of VEGF and TP were determined in the primary tumor by original immunometric methods. | 1002-1114 | 1,002 | 1,114 | The cytosolic levels of VEGF and @SUBJECT$ were determined @PREDICAT$ the @OBJECT$ by original immunometric methods. |
Fact | preserve | 927-934 | 927-934 | T61 | treated | TREATS | 927 | 934 | preserve | 940-967 | 955-967 | T57 | adjuvant chemotherapy | TherapeuticOrPreventiveProcedure | 940 | 967 | preserve | 860-868 | 860-868 | T52 | patients | PatientOrDisabledGroup | 860 | 868 | A21 | PATIENTS AND METHODS: We studied two groups of 137 and 164 patients with NPBC, median follow-up of 72 months for both, treated with adjuvant chemotherapy or hormone therapy, respectively. | 801-1001 | 801 | 1,001 | PATIENTS AND METHODS: We studied two groups of 137 and 164 @OBJECT$ with NPBC, median follow-up of 72 months for both, @PREDICAT$ with @SUBJECT$ or hormone therapy, respectively. |
Fact | preserve | 927-934 | 927-934 | T61 | treated | TREATS | 927 | 934 | preserve | 971-986 | 979-986 | T58 | hormone therapy | TherapeuticOrPreventiveProcedure | 971 | 986 | preserve | 860-868 | 860-868 | T52 | patients | PatientOrDisabledGroup | 860 | 868 | A23 | PATIENTS AND METHODS: We studied two groups of 137 and 164 patients with NPBC, median follow-up of 72 months for both, treated with adjuvant chemotherapy or hormone therapy, respectively. | 801-1001 | 801 | 1,001 | PATIENTS AND METHODS: We studied two groups of 137 and 164 @OBJECT$ with NPBC, median follow-up of 72 months for both, @PREDICAT$ with adjuvant chemotherapy or @SUBJECT$ , respectively. |
Fact | preserve | 3441-3448 | 3441-3448 | T221 | treated | TREATS | 3,441 | 3,448 | preserve | 3463-3466 | 3463-3466 | T215 | CMF | TherapeuticOrPreventiveProcedure | 3,463 | 3,466 | preserve | 3430-3434 | 3430-3434 | T213 | NPBC | NeoplasticProcess | 3,430 | 3,434 | A24 | DISCUSSION: The results of our study suggest that high levels of TP and low levels of VEGF characterize the patients with NPBC treated with adjuvant CMF who have the highest likelihood of favorable outcome. | 3301-3520 | 3,301 | 3,520 | DISCUSSION: The results of our study suggest that high levels of TP and low levels of VEGF characterize the patients with @OBJECT$ @PREDICAT$ with adjuvant @SUBJECT$ who have the highest likelihood of favorable outcome. |
Fact | preserve | 103-107 | 103-107 | T11 | with | PROCESS_OF | 103 | 107 | preserve | 122-135 | 129-135 | T6 | breast cancer | NeoplasticProcess | 122 | 135 | preserve | 94-102 | 94-102 | T4 | patients | PatientOrDisabledGroup | 94 | 102 | A25 | Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. | 0-203 | 0 | 203 | Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in @OBJECT$ @PREDICAT$ node-positive @SUBJECT$ treated with either adjuvant chemotherapy or hormone therapy. |
Fact | preserve | 2609-2623 | 2618-2623 | T159 | axillary nodes | LOCATION_OF | 2,609 | 2,623 | preserve | 2609-2617 | 2609-2617 | T153 | axillary | BodyLocationOrRegion | 2,609 | 2,617 | preserve | 2618-2623 | 2618-2623 | T154 | nodes | BodyPartOrganOrOrganComponent | 2,618 | 2,623 | A26 | Likewise, the number of involved axillary nodes was significantly associated with both RFS and OS. | 2576-2681 | 2,576 | 2,681 | Likewise, the number of involved @SUBJECT$ @PREDICAT$ @OBJECT$ was significantly associated with both RFS and OS. |
Fact | preserve | 3425-3429 | 3425-3429 | T220 | with | PROCESS_OF | 3,425 | 3,429 | preserve | 3430-3434 | 3430-3434 | T213 | NPBC | NeoplasticProcess | 3,430 | 3,434 | preserve | 3416-3424 | 3416-3424 | T211 | patients | PatientOrDisabledGroup | 3,416 | 3,424 | A27 | DISCUSSION: The results of our study suggest that high levels of TP and low levels of VEGF characterize the patients with NPBC treated with adjuvant CMF who have the highest likelihood of favorable outcome. | 3301-3520 | 3,301 | 3,520 | DISCUSSION: The results of our study suggest that high levels of TP and low levels of VEGF characterize the @OBJECT$ @PREDICAT$ @SUBJECT$ treated with adjuvant CMF who have the highest likelihood of favorable outcome. |
Fact | preserve | 876-880 | 876-880 | T59 | with | PROCESS_OF | 876 | 880 | preserve | 881-885 | 881-885 | T54 | NPBC | NeoplasticProcess | 881 | 885 | preserve | 860-868 | 860-868 | T52 | patients | PatientOrDisabledGroup | 860 | 868 | A28 | PATIENTS AND METHODS: We studied two groups of 137 and 164 patients with NPBC, median follow-up of 72 months for both, treated with adjuvant chemotherapy or hormone therapy, respectively. | 801-1001 | 801 | 1,001 | PATIENTS AND METHODS: We studied two groups of 137 and 164 @OBJECT$ @PREDICAT$ @SUBJECT$ , median follow-up of 72 months for both, treated with adjuvant chemotherapy or hormone therapy, respectively. |
Fact | preserve | 136-143 | 136-143 | T12 | treated | TREATS | 136 | 143 | preserve | 187-202 | 195-202 | T8 | hormone therapy | TherapeuticOrPreventiveProcedure | 187 | 202 | preserve | 122-135 | 129-135 | T6 | breast cancer | NeoplasticProcess | 122 | 135 | A29 | Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. | 0-203 | 0 | 203 | Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive @OBJECT$ @PREDICAT$ with either adjuvant chemotherapy or @SUBJECT$ . |
Fact | preserve | 927-934 | 927-934 | T61 | treated | TREATS | 927 | 934 | preserve | 971-986 | 979-986 | T58 | hormone therapy | TherapeuticOrPreventiveProcedure | 971 | 986 | preserve | 881-885 | 881-885 | T54 | NPBC | NeoplasticProcess | 881 | 885 | A30 | PATIENTS AND METHODS: We studied two groups of 137 and 164 patients with NPBC, median follow-up of 72 months for both, treated with adjuvant chemotherapy or hormone therapy, respectively. | 801-1001 | 801 | 1,001 | PATIENTS AND METHODS: We studied two groups of 137 and 164 patients with @OBJECT$ , median follow-up of 72 months for both, @PREDICAT$ with adjuvant chemotherapy or @SUBJECT$ , respectively. |
Fact | preserve | 927-934 | 927-934 | T61 | treated | TREATS | 927 | 934 | preserve | 940-967 | 955-967 | T57 | adjuvant chemotherapy | TherapeuticOrPreventiveProcedure | 940 | 967 | preserve | 881-885 | 881-885 | T54 | NPBC | NeoplasticProcess | 881 | 885 | A31 | PATIENTS AND METHODS: We studied two groups of 137 and 164 patients with NPBC, median follow-up of 72 months for both, treated with adjuvant chemotherapy or hormone therapy, respectively. | 801-1001 | 801 | 1,001 | PATIENTS AND METHODS: We studied two groups of 137 and 164 patients with @OBJECT$ , median follow-up of 72 months for both, @PREDICAT$ with @SUBJECT$ or hormone therapy, respectively. |
Fact | preserve | 273-277 | 273-277 | T18 | with | PROCESS_OF | 273 | 277 | preserve | 303-316 | 303-316 | T17 | complications | PathologicFunction | 303 | 316 | preserve | 264-272 | 264-272 | T16 | patients | PatientOrDisabledGroup | 264 | 272 | A1 | As the number of surgical procedures increases, so does the number of patients with postfundoplication complications. | 188-317 | 188 | 317 | As the number of surgical procedures increases, so does the number of @OBJECT$ @PREDICAT$ postfundoplication @SUBJECT$ . |
Fact | preserve | 760-764 | 760-764 | T50 | with | PROCESS_OF | 760 | 764 | preserve | 777-781 | 777-781 | T44 | GERD | DiseaseOrSyndrome | 777 | 781 | preserve | 751-759 | 751-759 | T42 | patients | PatientOrDisabledGroup | 751 | 759 | A2 | In patients with complicated GERD, the surgeon must be able to recognize severe disease and perform advanced procedures. | 748-874 | 748 | 874 | In @OBJECT$ @PREDICAT$ complicated @SUBJECT$ , the surgeon must be able to recognize severe disease and perform advanced procedures. |
Fact | preserve | 84-94 | 84-94 | T11 | management | TREATS | 84 | 94 | preserve | 69-76 | 69-76 | T5 | therapy | TherapeuticOrPreventiveProcedure | 69 | 76 | preserve | 98-129 | 122-129 | T7 | gastroesophageal reflux disease | DiseaseOrSyndrome | 98 | 129 | A3 | The role of surgical therapy in the management of gastroesophageal reflux disease (GERD) continues to evolve in the laparoscopic era. | 48-187 | 48 | 187 | The role of surgical @SUBJECT$ in the @PREDICAT$ of @OBJECT$ (GERD) continues to evolve in the laparoscopic era. |
Fact | preserve | 60-76 | 69-76 | T10 | surgical therapy | ISA | 60 | 76 | preserve | 60-68 | 60-68 | T4 | surgical | TherapeuticOrPreventiveProcedure | 60 | 68 | preserve | 69-76 | 69-76 | T5 | therapy | TherapeuticOrPreventiveProcedure | 69 | 76 | A4 | The role of surgical therapy in the management of gastroesophageal reflux disease (GERD) continues to evolve in the laparoscopic era. | 48-187 | 48 | 187 | The role of @SUBJECT$ @PREDICAT$ @OBJECT$ in the management of gastroesophageal reflux disease (GERD) continues to evolve in the laparoscopic era. |
Fact | preserve | 60-76 | 69-76 | T12 | surgical therapy | TREATS | 60 | 76 | preserve | 60-68 | 60-68 | T4 | surgical | TherapeuticOrPreventiveProcedure | 60 | 68 | preserve | 98-129 | 122-129 | T7 | gastroesophageal reflux disease | DiseaseOrSyndrome | 98 | 129 | A5 | The role of surgical therapy in the management of gastroesophageal reflux disease (GERD) continues to evolve in the laparoscopic era. | 48-187 | 48 | 187 | The role of @SUBJECT$ @PREDICAT$ in the management of @OBJECT$ (GERD) continues to evolve in the laparoscopic era. |
Fact | preserve | 530-539 | 530-539 | T29 | inhibited | INHIBITS | 530 | 539 | preserve | 513-523 | 520-523 | T25 | Cyclic AMP | BiologicallyActiveSubstance | 513 | 523 | preserve | 540-545 | 540-545 | T26 | CD40L | AminoAcidPeptideOrProtein | 540 | 545 | A1 | Cyclic AMP inhibited CD40L expression induced by TCR activation. | 513-583 | 513 | 583 | @SUBJECT$ @PREDICAT$ @OBJECT$ expression induced by TCR activation. |
Fact | preserve | 930-938 | 930-938 | T53 | increase | STIMULATES | 930 | 938 | preserve | 836-853 | 844-853 | T44 | calcium ionophore | IndicatorReagentOrDiagnosticAid | 836 | 853 | preserve | 939-944 | 939-944 | T49 | CD40L | AminoAcidPeptideOrProtein | 939 | 944 | A2 | While neither CD28 costimulation nor exogenous IL-2 or IL-4 prevented cAMP inhibition in TCR activated cells, addition of calcium ionophore to TCR activation prevented any inhibitory effects and caused cAMP to increase CD40L expression. | 708-962 | 708 | 962 | While neither CD28 costimulation nor exogenous IL-2 or IL-4 prevented cAMP inhibition in TCR activated cells, addition of @SUBJECT$ to TCR activation prevented any inhibitory effects and caused cAMP to @PREDICAT$ @OBJECT$ expression. |
Probable | preserve | 282-284 | 282-284 | T17 | in | TREATS | 282 | 284 | preserve | 246-261 | 246-261 | T12 | bronchodilators | PharmacologicSubstance | 246 | 261 | preserve | 285-291 | 285-291 | T13 | asthma | DiseaseOrSyndrome | 285 | 291 | A4 | Because cAMP mediates actions of bronchodilators commonly used in asthma, the effects of cAMP in regulating the immune response are of major importance. | 213-377 | 213 | 377 | Because cAMP mediates actions of @SUBJECT$ commonly used @PREDICAT$ @OBJECT$ , the effects of cAMP in regulating the immune response are of major importance. |
Fact | preserve | 0-10 | 0-10 | T6 | Regulation | INTERACTS_WITH | 0 | 10 | preserve | 34-44 | 41-44 | T4 | cyclic AMP | BiologicallyActiveSubstance | 34 | 44 | preserve | 14-19 | 14-19 | T2 | CD40L | AminoAcidPeptideOrProtein | 14 | 19 | A5 | Regulation of CD40L expression by cyclic AMP: contrasting proinflammatory and inhibitory actions. | 0-103 | 0 | 103 | @PREDICAT$ of @OBJECT$ expression by @SUBJECT$ : contrasting proinflammatory and inhibitory actions. |
Conditional | preserve | 429-437 | 429-437 | T24 | increase | STIMULATES | 429 | 437 | preserve | 378-388 | 385-388 | T18 | Cyclic AMP | BiologicallyActiveSubstance | 378 | 388 | preserve | 444-449 | 444-449 | T20 | CD40L | AminoAcidPeptideOrProtein | 444 | 449 | A6 | Cyclic AMP was found to either inhibit or markedly increase CD40L expression dependent upon the mechanisms of T cell activation. | 378-512 | 378 | 512 | @SUBJECT$ was found to either inhibit or markedly @PREDICAT$ @OBJECT$ expression dependent upon the mechanisms of T cell activation. |
Fact | preserve | 725-748 | 733-748 | T57 | cystine supplementation | USES | 725 | 748 | preserve | 733-748 | 733-748 | T50 | supplementation | TherapeuticOrPreventiveProcedure | 733 | 748 | preserve | 725-732 | 725-732 | T49 | cystine | AminoAcidPeptideOrProtein | 725 | 732 | A1 | Little effect of cystine supplementation was found on fecal sterol excretion although there were some changes in biliary excretion of cholic acid derivatives. | 708-878 | 708 | 878 | Little effect of @OBJECT$ @PREDICAT$ @SUBJECT$ was found on fecal sterol excretion although there were some changes in biliary excretion of cholic acid derivatives. |
Fact | preserve | 152-160 | 152-160 | T15 | resulted | CAUSES | 152 | 160 | preserve | 136-143 | 136-143 | T12 | cystine | AminoAcidPeptideOrProtein | 136 | 143 | preserve | 164-184 | 164-184 | T14 | hypercholesterolemia | DiseaseOrSyndrome | 164 | 184 | A3 | Feeding a diet with excess cystine to rats resulted in hypercholesterolemia. | 109-185 | 109 | 185 | Feeding a diet with excess @SUBJECT$ to rats @PREDICAT$ in @OBJECT$ . |
Fact | preserve | 38-40 | 38-40 | T9 | in | LOCATION_OF | 38 | 40 | preserve | 48-52 | 48-52 | T4 | rats | Mammal | 48 | 52 | preserve | 0-11 | 0-11 | T1 | Cholesterol | BiologicallyActiveSubstance | 0 | 11 | A4 | Cholesterol synthesis and degradation in normal rats fed a cholesterol-free diet with excess cystine. | 0-108 | 0 | 108 | @OBJECT$ synthesis and degradation @PREDICAT$ normal @SUBJECT$ fed a cholesterol-free diet with excess cystine. |
Counterfact | preserve | 1864-1875 | 1864-1875 | T91 | association | AFFECTS | 1,864 | 1,875 | preserve | 1813-1825 | 1813-1825 | T82 | appendectomy | TherapeuticOrPreventiveProcedure | 1,813 | 1,825 | preserve | 1910-1928 | 1921-1928 | T85 | ulcerative colitis | DiseaseOrSyndrome | 1,910 | 1,928 | A2 | The logistic regression analysis showed that appendectomy and tonsillectomy have no independent association with the risk of developing ulcerative colitis, whereas in Crohn's disease both appendectomy and tonsillectomy have positive associations. | 1761-2026 | 1,761 | 2,026 | The logistic regression analysis showed that @SUBJECT$ and tonsillectomy have no independent @PREDICAT$ with the risk of developing @OBJECT$ , whereas in Crohn's disease both appendectomy and tonsillectomy have positive associations. |
Fact | preserve | 2419-2430 | 2424-2430 | T112 | risk factor | PREDISPOSES | 2,419 | 2,430 | preserve | 2394-2407 | 2394-2407 | T109 | tonsillectomy | TherapeuticOrPreventiveProcedure | 2,394 | 2,407 | preserve | 2446-2461 | 2454-2461 | T111 | Crohn's disease | DiseaseOrSyndrome | 2,446 | 2,461 | A3 | Our data also support the conclusion that tonsillectomy is a risk factor for developing Crohn's disease. | 2352-2462 | 2,352 | 2,462 | Our data also support the conclusion that @SUBJECT$ is a @PREDICAT$ for developing @OBJECT$ . |
Fact | preserve | 582-622 | 615-622 | T42 | inflammatory bowel disease patient | PROCESS_OF | 582 | 622 | preserve | 582-608 | 601-608 | T30 | inflammatory bowel disease | DiseaseOrSyndrome | 582 | 608 | preserve | 615-622 | 615-622 | T31 | patient | PatientOrDisabledGroup | 615 | 622 | A4 | For each inflammatory bowel disease patient and a corresponding healthy control subject, matched for gender, age, and educational level, a standard record on various risk factors was completed by interview. | 573-797 | 573 | 797 | For each @SUBJECT$ @PREDICAT$ @OBJECT$ and a corresponding healthy control subject, matched for gender, age, and educational level, a standard record on various risk factors was completed by interview. |
Counterfact | preserve | 1864-1875 | 1864-1875 | T91 | association | AFFECTS | 1,864 | 1,875 | preserve | 1830-1843 | 1830-1843 | T83 | tonsillectomy | TherapeuticOrPreventiveProcedure | 1,830 | 1,843 | preserve | 1910-1928 | 1921-1928 | T85 | ulcerative colitis | DiseaseOrSyndrome | 1,910 | 1,928 | A5 | The logistic regression analysis showed that appendectomy and tonsillectomy have no independent association with the risk of developing ulcerative colitis, whereas in Crohn's disease both appendectomy and tonsillectomy have positive associations. | 1761-2026 | 1,761 | 2,026 | The logistic regression analysis showed that appendectomy and @SUBJECT$ have no independent @PREDICAT$ with the risk of developing @OBJECT$ , whereas in Crohn's disease both appendectomy and tonsillectomy have positive associations. |
Fact | preserve | 1221-1225 | 1221-1225 | T64 | with | PROCESS_OF | 1,221 | 1,225 | preserve | 1226-1241 | 1234-1241 | T58 | Crohn's disease | DiseaseOrSyndrome | 1,226 | 1,241 | preserve | 1212-1220 | 1212-1220 | T57 | patients | PatientOrDisabledGroup | 1,212 | 1,220 | A6 | RESULTS: Appendectomy had been performed in 11 (8.2 percent) patients with ulcerative colitis, in 18 (13.4 percent) of their matched healthy control cases, in 19 (25.0 percent) patients with Crohn's disease, and in 10 (13.2 percent) of their matched healthy control cases. | 1017-1313 | 1,017 | 1,313 | RESULTS: Appendectomy had been performed in 11 (8.2 percent) patients with ulcerative colitis, in 18 (13.4 percent) of their matched healthy control cases, in 19 (25.0 percent) @OBJECT$ @PREDICAT$ @SUBJECT$ , and in 10 (13.2 percent) of their matched healthy control cases. |
Uncommitted | preserve | 33-37 | 33-37 | T7 | risk | PREDISPOSES | 33 | 37 | preserve | 0-12 | 0-12 | T1 | Appendectomy | TherapeuticOrPreventiveProcedure | 0 | 12 | preserve | 41-67 | 60-67 | T4 | inflammatory bowel disease | DiseaseOrSyndrome | 41 | 67 | A7 | Appendectomy, tonsillectomy, and risk of inflammatory bowel disease: case-controlled study in Crete. | 0-106 | 0 | 106 | @SUBJECT$ , tonsillectomy, and @PREDICAT$ of @OBJECT$ : case-controlled study in Crete. |
Uncommitted | preserve | 33-37 | 33-37 | T7 | risk | PREDISPOSES | 33 | 37 | preserve | 14-27 | 14-27 | T2 | tonsillectomy | TherapeuticOrPreventiveProcedure | 14 | 27 | preserve | 41-67 | 60-67 | T4 | inflammatory bowel disease | DiseaseOrSyndrome | 41 | 67 | A8 | Appendectomy, tonsillectomy, and risk of inflammatory bowel disease: case-controlled study in Crete. | 0-106 | 0 | 106 | Appendectomy, @SUBJECT$ , and @PREDICAT$ of @OBJECT$ : case-controlled study in Crete. |
Fact | preserve | 2186-2191 | 2186-2191 | T107 | using | USES | 2,186 | 2,191 | preserve | 2166-2184 | 2179-2184 | T101 | case-control study | ResearchActivity | 2,166 | 2,184 | preserve | 2205-2233 | 2225-2233 | T102 | logistic regression analysis | QuantitativeConcept | 2,205 | 2,233 | A10 | CONCLUSIONS: This case-control study, using multivariate logistic regression analysis, showed a less pronounced association between ulcerative colitis and appendectomy than previous reports. | 2142-2351 | 2,142 | 2,351 | CONCLUSIONS: This @SUBJECT$ , @PREDICAT$ multivariate @OBJECT$ , showed a less pronounced association between ulcerative colitis and appendectomy than previous reports. |
Fact | preserve | 1093-1097 | 1093-1097 | T63 | with | PROCESS_OF | 1,093 | 1,097 | preserve | 1098-1122 | 1115-1122 | T52 | ulcerative colitis | DiseaseOrSyndrome | 1,098 | 1,122 | preserve | 1084-1092 | 1084-1092 | T51 | patients | PatientOrDisabledGroup | 1,084 | 1,092 | A11 | RESULTS: Appendectomy had been performed in 11 (8.2 percent) patients with ulcerative colitis, in 18 (13.4 percent) of their matched healthy control cases, in 19 (25.0 percent) patients with Crohn's disease, and in 10 (13.2 percent) of their matched healthy control cases. | 1017-1313 | 1,017 | 1,313 | RESULTS: Appendectomy had been performed in 11 (8.2 percent) @OBJECT$ @PREDICAT$ @SUBJECT$ , in 18 (13.4 percent) of their matched healthy control cases, in 19 (25.0 percent) patients with Crohn's disease, and in 10 (13.2 percent) of their matched healthy control cases. |
Fact | preserve | 775-779 | 775-779 | T63 | with | PROCESS_OF | 775 | 779 | preserve | 800-825 | 813-825 | T55 | intermittent claudication | DiseaseOrSyndrome | 800 | 825 | preserve | 769-774 | 769-774 | T53 | woman | PopulationGroup | 769 | 774 | A2 | Ankle-brachial index (ABI) and walking function were assessed in a 60-year-old woman with type 2 diabetes and intermittent claudication, before and after five sessions of TBFB applied to the ventral surface of the great toe. | 684-921 | 684 | 921 | Ankle-brachial index (ABI) and walking function were assessed in a 60-year-old @OBJECT$ @PREDICAT$ type 2 diabetes and @SUBJECT$ , before and after five sessions of TBFB applied to the ventral surface of the great toe. |
Fact | preserve | 409-413 | 409-413 | T26 | with | PROCESS_OF | 409 | 413 | preserve | 414-447 | 440-447 | T24 | peripheral vascular disease | DiseaseOrSyndrome | 414 | 447 | preserve | 400-408 | 400-408 | T23 | patients | PatientOrDisabledGroup | 400 | 408 | A6 | Toe TBFB may improve vascular flow and walking tolerance in patients with peripheral vascular disease. | 333-448 | 333 | 448 | Toe TBFB may improve vascular flow and walking tolerance in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 520-524 | 520-524 | T44 | with | PROCESS_OF | 520 | 524 | preserve | 541-554 | 541-554 | T33 | complications | PathologicFunction | 541 | 554 | preserve | 512-519 | 512-519 | T31 | patient | PatientOrDisabledGroup | 512 | 519 | A7 | This case study documents improved walking in a diabetes patient with lower extremity complications, and suggests TBFB might increase lower extremity temperature and blood flow volume pulse in uncomplicated diabetes. | 449-683 | 449 | 683 | This case study documents improved walking in a diabetes @OBJECT$ @PREDICAT$ lower extremity @SUBJECT$ , and suggests TBFB might increase lower extremity temperature and blood flow volume pulse in uncomplicated diabetes. |
Fact | preserve | 37-39 | 37-39 | T7 | in | COEXISTS_WITH | 37 | 39 | preserve | 24-36 | 24-36 | T2 | claudication | DiseaseOrSyndrome | 24 | 36 | preserve | 40-48 | 40-48 | T3 | diabetes | DiseaseOrSyndrome | 40 | 48 | A9 | Thermal biofeedback for claudication in diabetes: a literature review and case study. | 0-91 | 0 | 91 | Thermal biofeedback for @SUBJECT$ @PREDICAT$ @OBJECT$ : a literature review and case study. |
Fact | preserve | 775-779 | 775-779 | T63 | with | PROCESS_OF | 775 | 779 | preserve | 780-795 | 787-795 | T54 | type 2 diabetes | DiseaseOrSyndrome | 780 | 795 | preserve | 769-774 | 769-774 | T53 | woman | PopulationGroup | 769 | 774 | A10 | Ankle-brachial index (ABI) and walking function were assessed in a 60-year-old woman with type 2 diabetes and intermittent claudication, before and after five sessions of TBFB applied to the ventral surface of the great toe. | 684-921 | 684 | 921 | Ankle-brachial index (ABI) and walking function were assessed in a 60-year-old @OBJECT$ @PREDICAT$ @SUBJECT$ and intermittent claudication, before and after five sessions of TBFB applied to the ventral surface of the great toe. |
Uncommitted | preserve | 20-23 | 20-23 | T6 | for | TREATS | 20 | 23 | preserve | 0-19 | 8-19 | T1 | Thermal biofeedback | TherapeuticOrPreventiveProcedure | 0 | 19 | preserve | 24-36 | 24-36 | T2 | claudication | DiseaseOrSyndrome | 24 | 36 | A11 | Thermal biofeedback for claudication in diabetes: a literature review and case study. | 0-91 | 0 | 91 | @SUBJECT$ @PREDICAT$ @OBJECT$ in diabetes: a literature review and case study. |
Probable | preserve | 353-360 | 353-360 | T25 | improve | AFFECTS | 353 | 360 | preserve | 337-341 | 337-341 | T20 | TBFB | PhysiologicFunction | 337 | 341 | preserve | 361-374 | 370-374 | T21 | vascular flow | OrganismFunction | 361 | 374 | A13 | Toe TBFB may improve vascular flow and walking tolerance in patients with peripheral vascular disease. | 333-448 | 333 | 448 | Toe @SUBJECT$ may @PREDICAT$ @OBJECT$ and walking tolerance in patients with peripheral vascular disease. |
Fact | preserve | 497-519 | 512-519 | T42 | diabetes patient | PROCESS_OF | 497 | 519 | preserve | 497-505 | 497-505 | T30 | diabetes | DiseaseOrSyndrome | 497 | 505 | preserve | 512-519 | 512-519 | T31 | patient | PatientOrDisabledGroup | 512 | 519 | A15 | This case study documents improved walking in a diabetes patient with lower extremity complications, and suggests TBFB might increase lower extremity temperature and blood flow volume pulse in uncomplicated diabetes. | 449-683 | 449 | 683 | This case study documents improved walking in a @SUBJECT$ @PREDICAT$ @OBJECT$ with lower extremity complications, and suggests TBFB might increase lower extremity temperature and blood flow volume pulse in uncomplicated diabetes. |
Fact | preserve | 1241-1243 | 1241-1243 | T88 | in | ASSOCIATED_WITH | 1,241 | 1,243 | preserve | 1208-1216 | 1208-1216 | T84 | vascular | BodyPartOrganOrOrganComponent | 1,208 | 1,216 | preserve | 1259-1271 | 1259-1271 | T87 | claudication | DiseaseOrSyndrome | 1,259 | 1,271 | A16 | This case indicates the need for extended and controlled study of TBFB for improved vascular and ambulatory function in diabetic claudication. | 1118-1272 | 1,118 | 1,272 | This case indicates the need for extended and controlled study of TBFB for improved @SUBJECT$ and ambulatory function @PREDICAT$ diabetic @OBJECT$ . |
Fact | preserve | 1560-1564 | 1560-1564 | T102 | with | PROCESS_OF | 1,560 | 1,564 | preserve | 1565-1569 | 1565-1569 | T96 | COPD | DiseaseOrSyndrome | 1,565 | 1,569 | preserve | 1545-1553 | 1545-1553 | T95 | patients | PatientOrDisabledGroup | 1,545 | 1,553 | A1 | NO in exhaled air correlated with the percentage of sputum eosinophils in patients with COPD (rho = 0.65, p = 0.009) but not in healthy individuals. | 1465-1625 | 1,465 | 1,625 | NO in exhaled air correlated with the percentage of sputum eosinophils in @OBJECT$ @PREDICAT$ @SUBJECT$ (rho = 0.65, p = 0.009) but not in healthy individuals. |
Fact | preserve | 1953-1955 | 1953-1955 | T127 | in | ASSOCIATED_WITH | 1,953 | 1,955 | preserve | 1950-1952 | 1950-1952 | T124 | NO | BiologicallyActiveSubstance | 1,950 | 1,952 | preserve | 1963-1975 | 1963-1975 | T125 | inflammation | PathologicFunction | 1,963 | 1,975 | A3 | The close association between exhaled NO levels and sputum eosinophils suggests a role for NO in airway inflammation in COPD. | 1852-1990 | 1,852 | 1,990 | The close association between exhaled NO levels and sputum eosinophils suggests a role for @SUBJECT$ @PREDICAT$ airway @OBJECT$ in COPD. |
Fact | preserve | 521-531 | 521-531 | T42 | expression | PART_OF | 521 | 531 | preserve | 516-520 | 516-520 | T27 | iNOS | AminoAcidPeptideOrProtein | 516 | 520 | preserve | 542-547 | 542-547 | T30 | cells | Cell | 542 | 547 | A4 | A study was undertaken to determine whether markers of NO metabolism (NO in exhaled air, iNOS expression in sputum cells, and nitrite + nitrate (NO2-/NO3-) in sputum supernatant) are increased in subjects with COPD, and whether they correlate with inflammatory indices in induced sputum. | 421-732 | 421 | 732 | A study was undertaken to determine whether markers of NO metabolism (NO in exhaled air, @SUBJECT$ @PREDICAT$ in sputum @OBJECT$ , and nitrite + nitrate (NO2-/NO3-) in sputum supernatant) are increased in subjects with COPD, and whether they correlate with inflammatory indices in induced sputum. |
Fact | preserve | 1364-1379 | 1375-1379 | T88 | macrophage iNOS | PART_OF | 1,364 | 1,379 | preserve | 1375-1379 | 1375-1379 | T82 | iNOS | AminoAcidPeptideOrProtein | 1,375 | 1,379 | preserve | 1364-1374 | 1364-1374 | T81 | macrophage | Cell | 1,364 | 1,374 | A6 | RESULTS: No differences were observed between subjects with COPD and healthy controls in exhaled NO excretion rate (median 5.15 and 6.25 nmol/min), sputum macrophage iNOS expression (14% and 12%), and sputum supernatant NO2-/NO3- (46 and 73 microM). | 1196-1464 | 1,196 | 1,464 | RESULTS: No differences were observed between subjects with COPD and healthy controls in exhaled NO excretion rate (median 5.15 and 6.25 nmol/min), sputum @OBJECT$ @PREDICAT$ @SUBJECT$ expression (14% and 12%), and sputum supernatant NO2-/NO3- (46 and 73 microM). |
Fact | preserve | 160-168 | 160-168 | T10 | involved | ASSOCIATED_WITH | 160 | 168 | preserve | 139-151 | 146-151 | T6 | Nitric oxide | BiologicallyActiveSubstance | 139 | 151 | preserve | 172-184 | 172-184 | T7 | inflammation | PathologicFunction | 172 | 184 | A9 | BACKGROUND: Nitric oxide (NO) is involved in inflammation and host defence of the lung. | 127-220 | 127 | 220 | BACKGROUND: @SUBJECT$ (NO) is @PREDICAT$ in @OBJECT$ and host defence of the lung. |
Fact | preserve | 337-341 | 337-341 | T21 | with | PROCESS_OF | 337 | 341 | preserve | 342-379 | 372-379 | T18 | chronic obstructive pulmonary disease | DiseaseOrSyndrome | 342 | 379 | preserve | 328-336 | 328-336 | T17 | patients | PatientOrDisabledGroup | 328 | 336 | A10 | It has been found in increased concentrations in the airways in asthmatic subjects but its levels in patients with chronic obstructive pulmonary disease (COPD) have not been investigated. | 221-420 | 221 | 420 | It has been found in increased concentrations in the airways in asthmatic subjects but its levels in @OBJECT$ @PREDICAT$ @SUBJECT$ (COPD) have not been investigated. |
Fact | preserve | 1834-1838 | 1834-1838 | T118 | with | PROCESS_OF | 1,834 | 1,838 | preserve | 1846-1850 | 1846-1850 | T117 | COPD | DiseaseOrSyndrome | 1,846 | 1,850 | preserve | 1825-1833 | 1825-1833 | T116 | patients | PatientOrDisabledGroup | 1,825 | 1,833 | A11 | CONCLUSIONS: Our findings indicate that NO metabolism is not increased in patients with stable COPD. | 1745-1851 | 1,745 | 1,851 | CONCLUSIONS: Our findings indicate that NO metabolism is not increased in @OBJECT$ @PREDICAT$ stable @SUBJECT$ . |
Fact | preserve | 592-610 | 599-610 | T43 | sputum supernatant | PART_OF | 592 | 610 | preserve | 599-610 | 599-610 | T35 | supernatant | BodySubstance | 599 | 610 | preserve | 592-598 | 592-598 | T34 | sputum | BodySubstance | 592 | 598 | A12 | A study was undertaken to determine whether markers of NO metabolism (NO in exhaled air, iNOS expression in sputum cells, and nitrite + nitrate (NO2-/NO3-) in sputum supernatant) are increased in subjects with COPD, and whether they correlate with inflammatory indices in induced sputum. | 421-732 | 421 | 732 | A study was undertaken to determine whether markers of NO metabolism (NO in exhaled air, iNOS expression in sputum cells, and nitrite + nitrate (NO2-/NO3-) in @OBJECT$ @PREDICAT$ @SUBJECT$ ) are increased in subjects with COPD, and whether they correlate with inflammatory indices in induced sputum. |
Possible | preserve | 1068-1070 | 1068-1070 | T57 | in | TREATS | 1,068 | 1,070 | preserve | 1034-1041 | 1034-1041 | T47 | regimen | ResearchActivity | 1,034 | 1,041 | preserve | 1086-1098 | 1086-1098 | T50 | hypertension | DiseaseOrSyndrome | 1,086 | 1,098 | A1 | Therefore, an antihypertensive regimen would be safe even in extreme-dipper hypertension without excessive nocturnal hypotension, and might even be beneficial because of the decreasing amplitude and speed of the nocturnal BP decline. | 1003-1255 | 1,003 | 1,255 | Therefore, an antihypertensive @SUBJECT$ would be safe even @PREDICAT$ extreme-dipper @OBJECT$ without excessive nocturnal hypotension, and might even be beneficial because of the decreasing amplitude and speed of the nocturnal BP decline. |
Fact | preserve | 1276-1305 | 1298-1305 | T63 | antihypertensive drug regimen | USES | 1,276 | 1,305 | preserve | 1298-1305 | 1298-1305 | T59 | regimen | ResearchActivity | 1,298 | 1,305 | preserve | 1276-1297 | 1293-1297 | T58 | antihypertensive drug | PharmacologicSubstance | 1,276 | 1,297 | A3 | We conclude that an antihypertensive drug regimen should control BP throughout a 24-h period regardless of circadian BP variation. | 1256-1392 | 1,256 | 1,392 | We conclude that an @OBJECT$ @PREDICAT$ @SUBJECT$ should control BP throughout a 24-h period regardless of circadian BP variation. |
Fact | preserve | 644-653 | 644-653 | T33 | underwent | TREATS | 644 | 653 | preserve | 671-680 | 671-680 | T32 | procedure | HealthCareActivity | 671 | 680 | preserve | 611-627 | 619-627 | T29 | cardiac patients | PatientOrDisabledGroup | 611 | 627 | A1 | RESULTS: Prophylactic antibiotics were not given before infective endocarditis to 8/11 cardiac patients at risk and who underwent an at risk procedure. | 518-681 | 518 | 681 | RESULTS: Prophylactic antibiotics were not given before infective endocarditis to 8/11 @OBJECT$ at risk and who @PREDICAT$ an at risk @SUBJECT$ . |
Counterfact | preserve | 914-917 | 914-917 | T47 | for | TREATS | 914 | 917 | preserve | 881-899 | 892-899 | T45 | antibiotic therapy | TherapeuticOrPreventiveProcedure | 881 | 899 | preserve | 927-935 | 927-935 | T46 | patients | PatientOrDisabledGroup | 927 | 935 | A2 | In-hospital antibiotic therapy was incorrect for 23 patients. | 869-936 | 869 | 936 | In-hospital @SUBJECT$ was incorrect @PREDICAT$ 23 @OBJECT$ . |
Fact | preserve | 724-728 | 724-728 | T42 | with | PROCESS_OF | 724 | 728 | preserve | 729-734 | 729-734 | T36 | fever | Finding | 729 | 734 | preserve | 695-711 | 703-711 | T34 | cardiac patients | PatientOrDisabledGroup | 695 | 711 | A6 | Among the 55 cardiac patients at risk and with fever and who consulted a physician, blood cultures were not performed before antibiotic therapy was initiated for 32 patients. | 682-868 | 682 | 868 | Among the 55 @OBJECT$ at risk and @PREDICAT$ @SUBJECT$ and who consulted a physician, blood cultures were not performed before antibiotic therapy was initiated for 32 patients. |
Fact | preserve | 1060-1063 | 1060-1063 | T66 | had | PROCESS_OF | 1,060 | 1,063 | preserve | 1071-1084 | 1077-1084 | T55 | heart failure | DiseaseOrSyndrome | 1,071 | 1,084 | preserve | 1047-1055 | 1047-1055 | T53 | patients | PatientOrDisabledGroup | 1,047 | 1,055 | A7 | Among the 19 patients who had severe heart failure or fever persisting more than 2 weeks in spite of antibiotic therapy and who could have undergone early surgery, surgery was delayed for five, and not performed for three. | 1034-1274 | 1,034 | 1,274 | Among the 19 @OBJECT$ who @PREDICAT$ severe @SUBJECT$ or fever persisting more than 2 weeks in spite of antibiotic therapy and who could have undergone early surgery, surgery was delayed for five, and not performed for three. |
Fact | preserve | 621-653 | 645-653 | T48 | renal failure (prerenal azotemia | ISA | 621 | 653 | preserve | 636-653 | 645-653 | T39 | prerenal azotemia | DiseaseOrSyndrome | 636 | 653 | preserve | 621-634 | 627-634 | T38 | renal failure | DiseaseOrSyndrome | 621 | 634 | A1 | The major causes of diuretic resistance are functional renal failure (prerenal azotemia), hyponatremia, altered diuretic pharmacokinetics, and sodium retention caused by counterregulatory mechanisms intended to reestablish the effective arterial blood volume. | 560-843 | 560 | 843 | The major causes of diuretic resistance are functional @OBJECT$ @PREDICAT$ @SUBJECT$ ), hyponatremia, altered diuretic pharmacokinetics, and sodium retention caused by counterregulatory mechanisms intended to reestablish the effective arterial blood volume. |
Fact | preserve | 317-324 | 317-324 | T21 | improve | TREATS | 317 | 324 | preserve | 269-283 | 274-283 | T18 | loop diuretics | PharmacologicSubstance | 269 | 283 | preserve | 325-333 | 325-333 | T19 | symptoms | SignOrSymptom | 325 | 333 | A3 | In advanced symptomatic heart failure, loop diuretics are generally necessary to improve symptoms of congestion. | 224-348 | 224 | 348 | In advanced symptomatic heart failure, @SUBJECT$ are generally necessary to @PREDICAT$ @OBJECT$ of congestion. |
Fact | preserve | 43-45 | 43-45 | T4 | in | TREATS | 43 | 45 | preserve | 0-18 | 9-18 | T1 | Diuretic treatment | TherapeuticOrPreventiveProcedure | 0 | 18 | preserve | 46-59 | 52-59 | T3 | heart failure | DiseaseOrSyndrome | 46 | 59 | A6 | Diuretic treatment and diuretic resistance in heart failure. | 0-60 | 0 | 60 | @SUBJECT$ and diuretic resistance @PREDICAT$ @OBJECT$ . |
Fact | preserve | 88-112 | 104-112 | T15 | capillary wedge pressure | LOCATION_OF | 88 | 112 | preserve | 88-97 | 88-97 | T7 | capillary | BodyPartOrganOrOrganComponent | 88 | 97 | preserve | 98-112 | 104-112 | T8 | wedge pressure | LaboratoryOrTestResult | 98 | 112 | A8 | Diuretic therapy decreases capillary wedge pressure and improves New York Heart Association (NYHA) functional class both in acute and chronic heart failure. | 61-223 | 61 | 223 | Diuretic therapy decreases @SUBJECT$ @PREDICAT$ @OBJECT$ and improves New York Heart Association (NYHA) functional class both in acute and chronic heart failure. |
Fact | preserve | 376-393 | 386-393 | T31 | edematous patient | PROCESS_OF | 376 | 393 | preserve | 376-385 | 376-385 | T23 | edematous | PathologicFunction | 376 | 385 | preserve | 386-393 | 386-393 | T24 | patient | PatientOrDisabledGroup | 386 | 393 | A10 | Diuretic resistance in the edematous patient has been defined as a clinical state in which diuretic response is diminished or lost before the therapeutic goal of relief from edema has been reached. | 349-559 | 349 | 559 | Diuretic resistance in the @SUBJECT$ @PREDICAT$ @OBJECT$ has been defined as a clinical state in which diuretic response is diminished or lost before the therapeutic goal of relief from edema has been reached. |
Fact | preserve | 146-155 | 146-155 | T18 | treatment | TREATS | 146 | 155 | preserve | 89-105 | 100-105 | T10 | -rheumatic drugs | PharmacologicSubstance | 89 | 105 | preserve | 159-167 | 159-167 | T12 | patients | PatientOrDisabledGroup | 159 | 167 | A1 | Several kinds of disease modifying anti-rheumatic drugs (DMARDs) can be utilized for the treatment of patients with rheumatoid arthritis (RA) to expect the prevention of joint damage progression and the improvement of quality of life. | 50-297 | 50 | 297 | Several kinds of disease modifying anti @SUBJECT$ (DMARDs) can be utilized for the @PREDICAT$ of @OBJECT$ with rheumatoid arthritis (RA) to expect the prevention of joint damage progression and the improvement of quality of life. |
Fact | preserve | 481-492 | 481-492 | T40 | suppression | DISRUPTS | 481 | 492 | preserve | 438-444 | 438-444 | T34 | DMARDs | PharmacologicSubstance | 438 | 444 | preserve | 503-510 | 503-510 | T39 | disease | DiseaseOrSyndrome | 503 | 510 | A2 | On the basis of our prospective study, earlier introduction of DMARDs can be more efficient for the suppression of active disease. | 369-511 | 369 | 511 | On the basis of our prospective study, earlier introduction of @SUBJECT$ can be more efficient for the @PREDICAT$ of active @OBJECT$ . |
Fact | preserve | 146-155 | 146-155 | T18 | treatment | TREATS | 146 | 155 | preserve | 89-105 | 100-105 | T10 | -rheumatic drugs | PharmacologicSubstance | 89 | 105 | preserve | 173-193 | 184-193 | T13 | rheumatoid arthritis | DiseaseOrSyndrome | 173 | 193 | A3 | Several kinds of disease modifying anti-rheumatic drugs (DMARDs) can be utilized for the treatment of patients with rheumatoid arthritis (RA) to expect the prevention of joint damage progression and the improvement of quality of life. | 50-297 | 50 | 297 | Several kinds of disease modifying anti @SUBJECT$ (DMARDs) can be utilized for the @PREDICAT$ of patients with @OBJECT$ (RA) to expect the prevention of joint damage progression and the improvement of quality of life. |
Fact | preserve | 969-973 | 969-973 | T69 | with | PROCESS_OF | 969 | 973 | preserve | 987-989 | 987-989 | T66 | RA | DiseaseOrSyndrome | 987 | 989 | preserve | 960-968 | 960-968 | T64 | patients | PatientOrDisabledGroup | 960 | 968 | A4 | And if these situation will not change even 6 months after starting the therapy, we should make all possible efforts to lead patients into remission using DMARD or corticosteroids, which would prevent patients from disability of joint function and thus would improve the quality of life of patients with early RA. | 650-990 | 650 | 990 | And if these situation will not change even 6 months after starting the therapy, we should make all possible efforts to lead patients into remission using DMARD or corticosteroids, which would prevent patients from disability of joint function and thus would improve the quality of life of @OBJECT$ @PREDICAT$ early @SUBJECT$ . |
Fact | preserve | 168-172 | 168-172 | T19 | with | PROCESS_OF | 168 | 172 | preserve | 173-193 | 184-193 | T13 | rheumatoid arthritis | DiseaseOrSyndrome | 173 | 193 | preserve | 159-167 | 159-167 | T12 | patients | PatientOrDisabledGroup | 159 | 167 | A6 | Several kinds of disease modifying anti-rheumatic drugs (DMARDs) can be utilized for the treatment of patients with rheumatoid arthritis (RA) to expect the prevention of joint damage progression and the improvement of quality of life. | 50-297 | 50 | 297 | Several kinds of disease modifying anti-rheumatic drugs (DMARDs) can be utilized for the treatment of @OBJECT$ @PREDICAT$ @SUBJECT$ (RA) to expect the prevention of joint damage progression and the improvement of quality of life. |
Fact | preserve | 858-860 | 858-860 | T65 | in | LOCATION_OF | 858 | 860 | preserve | 861-868 | 861-868 | T60 | bronchi | BodyPartOrganOrOrganComponent | 861 | 868 | preserve | 817-825 | 817-825 | T56 | fibrosis | PathologicFunction | 817 | 825 | A2 | Both the area proportions of degenerated cartilage (Deg%) and perichondrial fibrosis (Fib%) to total cartilage in bronchi (3 to 8 mm in diameter), cut vertically in the cross-section profile, were measured with a digitizing tablet coupled to a computer. | 735-1007 | 735 | 1,007 | Both the area proportions of degenerated cartilage (Deg%) and perichondrial @OBJECT$ (Fib%) to total cartilage @PREDICAT$ @SUBJECT$ (3 to 8 mm in diameter), cut vertically in the cross-section profile, were measured with a digitizing tablet coupled to a computer. |
Fact | preserve | 1404-1406 | 1404-1406 | T85 | in | LOCATION_OF | 1,404 | 1,406 | preserve | 1411-1426 | 1421-1426 | T84 | bronchial walls | BodyPartOrganOrOrganComponent | 1,411 | 1,426 | preserve | 1392-1403 | 1392-1403 | T83 | neutrophils | Cell | 1,392 | 1,403 | A3 | The Deg% values correlated significantly with the number of neutrophils in the bronchial walls (r = 0.63, p < 0. | 1326-1444 | 1,326 | 1,444 | The Deg% values correlated significantly with the number of @OBJECT$ @PREDICAT$ the @SUBJECT$ (r = 0.63, p < 0. |
Fact | preserve | 1774-1776 | 1774-1776 | T104 | in | LOCATION_OF | 1,774 | 1,776 | preserve | 1781-1796 | 1791-1796 | T97 | bronchial walls | BodyPartOrganOrOrganComponent | 1,781 | 1,796 | preserve | 1762-1773 | 1762-1773 | T96 | eosinophils | Cell | 1,762 | 1,773 | A4 | The values of Fib% correlated significantly with the number of eosinophils in the bronchial walls (r = 0.51, p < 0.05), thickness of basement membrane (r = 0.77, p < 0.0002), bronchial gland area (r = 0.56, p < 0.02), and goblet-cell area (r = 0.55, p < 0.02). | 1692-1977 | 1,692 | 1,977 | The values of Fib% correlated significantly with the number of @OBJECT$ @PREDICAT$ the @SUBJECT$ (r = 0.51, p < 0.05), thickness of basement membrane (r = 0.77, p < 0.0002), bronchial gland area (r = 0.56, p < 0.02), and goblet-cell area (r = 0.55, p < 0.02). |
Fact | preserve | 22-24 | 22-24 | T5 | of | LOCATION_OF | 22 | 24 | preserve | 25-44 | 35-44 | T2 | bronchial cartilage | BodyPartOrganOrOrganComponent | 25 | 44 | preserve | 0-21 | 13-21 | T1 | Morphometric analysis | LaboratoryProcedure | 0 | 21 | A5 | Morphometric analysis of bronchial cartilage in chronic obstructive pulmonary disease and bronchial asthma. | 0-113 | 0 | 113 | @OBJECT$ @PREDICAT$ @SUBJECT$ in chronic obstructive pulmonary disease and bronchial asthma. |
Fact | preserve | 267-271 | 267-271 | T32 | with | ASSOCIATED_WITH | 267 | 271 | preserve | 246-251 | 246-251 | T15 | lungs | BodyPartOrganOrOrganComponent | 246 | 251 | preserve | 272-296 | 286-296 | T17 | chronic bronchitis | DiseaseOrSyndrome | 272 | 296 | A7 | To clarify the changes in bronchial cartilage in diseased airways, we performed morphometric analysis of airways in autopsied lungs of 16 patients with chronic bronchitis (Group CB), pulmonary emphysema (Group PE), and bronchial asthma (Group BA), and in control patients without respiratory diseases (Group CN). | 114-444 | 114 | 444 | To clarify the changes in bronchial cartilage in diseased airways, we performed morphometric analysis of airways in autopsied @SUBJECT$ of 16 patients @PREDICAT$ @OBJECT$ (Group CB), pulmonary emphysema (Group PE), and bronchial asthma (Group BA), and in control patients without respiratory diseases (Group CN). |
Fact | preserve | 467-469 | 467-469 | T42 | of | LOCATION_OF | 467 | 469 | preserve | 470-489 | 480-489 | T35 | bronchial cartilage | BodyPartOrganOrOrganComponent | 470 | 489 | preserve | 454-466 | 454-466 | T34 | degeneration | PathologicFunction | 454 | 466 | A9 | Although degeneration of bronchial cartilage was clearly observed in airways from all groups except Group CN, the most extreme change was seen in Group CB. | 445-606 | 445 | 606 | Although @OBJECT$ @PREDICAT$ @SUBJECT$ was clearly observed in airways from all groups except Group CN, the most extreme change was seen in Group CB. |
Fact | preserve | 45-47 | 45-47 | T6 | in | DIAGNOSES | 45 | 47 | preserve | 0-21 | 13-21 | T1 | Morphometric analysis | LaboratoryProcedure | 0 | 21 | preserve | 96-112 | 106-112 | T4 | bronchial asthma | DiseaseOrSyndrome | 96 | 112 | A11 | Morphometric analysis of bronchial cartilage in chronic obstructive pulmonary disease and bronchial asthma. | 0-113 | 0 | 113 | @SUBJECT$ of bronchial cartilage @PREDICAT$ chronic obstructive pulmonary disease and @OBJECT$ . |
Fact | preserve | 2323-2325 | 2323-2325 | T126 | in | LOCATION_OF | 2,323 | 2,325 | preserve | 2326-2345 | 2336-2345 | T120 | bronchial cartilage | BodyPartOrganOrOrganComponent | 2,326 | 2,345 | preserve | 2280-2288 | 2280-2288 | T118 | fibrosis | PathologicFunction | 2,280 | 2,288 | A12 | These findings indicate that airways in chronic obstructive pulmonary disease and bronchial asthma have both degenerative changes in the cartilage (chondrocytes) and increased perichondrial fibrosis, and that these alterations in bronchial cartilage may differ in chronic bronchitis and bronchial asthma. | 2078-2406 | 2,078 | 2,406 | These findings indicate that airways in chronic obstructive pulmonary disease and bronchial asthma have both degenerative changes in the cartilage (chondrocytes) and increased perichondrial @OBJECT$ , and that these alterations @PREDICAT$ @SUBJECT$ may differ in chronic bronchitis and bronchial asthma. |
Fact | preserve | 267-271 | 267-271 | T30 | with | PROCESS_OF | 267 | 271 | preserve | 272-296 | 286-296 | T17 | chronic bronchitis | DiseaseOrSyndrome | 272 | 296 | preserve | 258-266 | 258-266 | T16 | patients | PatientOrDisabledGroup | 258 | 266 | A13 | To clarify the changes in bronchial cartilage in diseased airways, we performed morphometric analysis of airways in autopsied lungs of 16 patients with chronic bronchitis (Group CB), pulmonary emphysema (Group PE), and bronchial asthma (Group BA), and in control patients without respiratory diseases (Group CN). | 114-444 | 114 | 444 | To clarify the changes in bronchial cartilage in diseased airways, we performed morphometric analysis of airways in autopsied lungs of 16 @OBJECT$ @PREDICAT$ @SUBJECT$ (Group CB), pulmonary emphysema (Group PE), and bronchial asthma (Group BA), and in control patients without respiratory diseases (Group CN). |
Fact | preserve | 252-254 | 252-254 | T28 | of | PART_OF | 252 | 254 | preserve | 246-251 | 246-251 | T15 | lungs | BodyPartOrganOrOrganComponent | 246 | 251 | preserve | 395-403 | 395-403 | T24 | patients | PatientOrDisabledGroup | 395 | 403 | A14 | To clarify the changes in bronchial cartilage in diseased airways, we performed morphometric analysis of airways in autopsied lungs of 16 patients with chronic bronchitis (Group CB), pulmonary emphysema (Group PE), and bronchial asthma (Group BA), and in control patients without respiratory diseases (Group CN). | 114-444 | 114 | 444 | To clarify the changes in bronchial cartilage in diseased airways, we performed morphometric analysis of airways in autopsied @SUBJECT$ @PREDICAT$ 16 patients with chronic bronchitis (Group CB), pulmonary emphysema (Group PE), and bronchial asthma (Group BA), and in control @OBJECT$ without respiratory diseases (Group CN). |
Fact | preserve | 45-47 | 45-47 | T6 | in | DIAGNOSES | 45 | 47 | preserve | 0-21 | 13-21 | T1 | Morphometric analysis | LaboratoryProcedure | 0 | 21 | preserve | 48-91 | 84-91 | T3 | chronic obstructive pulmonary disease | DiseaseOrSyndrome | 48 | 91 | A16 | Morphometric analysis of bronchial cartilage in chronic obstructive pulmonary disease and bronchial asthma. | 0-113 | 0 | 113 | @SUBJECT$ of bronchial cartilage @PREDICAT$ @OBJECT$ and bronchial asthma. |
Fact | preserve | 252-254 | 252-254 | T28 | of | PART_OF | 252 | 254 | preserve | 246-251 | 246-251 | T15 | lungs | BodyPartOrganOrOrganComponent | 246 | 251 | preserve | 258-266 | 258-266 | T16 | patients | PatientOrDisabledGroup | 258 | 266 | A17 | To clarify the changes in bronchial cartilage in diseased airways, we performed morphometric analysis of airways in autopsied lungs of 16 patients with chronic bronchitis (Group CB), pulmonary emphysema (Group PE), and bronchial asthma (Group BA), and in control patients without respiratory diseases (Group CN). | 114-444 | 114 | 444 | To clarify the changes in bronchial cartilage in diseased airways, we performed morphometric analysis of airways in autopsied @SUBJECT$ @PREDICAT$ 16 @OBJECT$ with chronic bronchitis (Group CB), pulmonary emphysema (Group PE), and bronchial asthma (Group BA), and in control patients without respiratory diseases (Group CN). |
Fact | preserve | 2357-2359 | 2357-2359 | T128 | in | COEXISTS_WITH | 2,357 | 2,359 | preserve | 2193-2213 | 2206-2213 | T113 | degenerative changes | PathologicFunction | 2,193 | 2,213 | preserve | 2360-2378 | 2368-2378 | T121 | chronic bronchitis | DiseaseOrSyndrome | 2,360 | 2,378 | A19 | These findings indicate that airways in chronic obstructive pulmonary disease and bronchial asthma have both degenerative changes in the cartilage (chondrocytes) and increased perichondrial fibrosis, and that these alterations in bronchial cartilage may differ in chronic bronchitis and bronchial asthma. | 2078-2406 | 2,078 | 2,406 | These findings indicate that airways in chronic obstructive pulmonary disease and bronchial asthma have both @SUBJECT$ in the cartilage (chondrocytes) and increased perichondrial fibrosis, and that these alterations in bronchial cartilage may differ @PREDICAT$ @OBJECT$ and bronchial asthma. |
Fact | preserve | 854-856 | 854-856 | T57 | in | COEXISTS_WITH | 854 | 856 | preserve | 788-809 | 801-809 | T50 | type 2 diabetes | DiseaseOrSyndrome | 788 | 809 | preserve | 866-879 | 866-879 | T55 | complications | PathologicFunction | 866 | 879 | A1 | It suggests that active and aggressive management of type 2 diabetes in general practice can have a role to play in reducing complications from diabetes. | 735-900 | 735 | 900 | It suggests that active and aggressive management of @SUBJECT$ in general practice can have a role to play @PREDICAT$ reducing @OBJECT$ from diabetes. |
Fact | preserve | 204-208 | 204-208 | T20 | with | PROCESS_OF | 204 | 208 | preserve | 209-217 | 209-217 | T17 | diabetes | DiseaseOrSyndrome | 209 | 217 | preserve | 197-203 | 197-203 | T16 | People | PopulationGroup | 197 | 203 | A2 | People with diabetes generally have sub-optimal glycaemic control. | 197-269 | 197 | 269 | @OBJECT$ @PREDICAT$ @SUBJECT$ generally have sub-optimal glycaemic control. |
Fact | preserve | 315-328 | 315-328 | T29 | characterised | ASSOCIATED_WITH | 315 | 328 | preserve | 343-350 | 343-350 | T25 | glucose | BiologicallyActiveSubstance | 343 | 350 | preserve | 297-305 | 297-305 | T23 | diabetes | DiseaseOrSyndrome | 297 | 305 | A4 | The natural progression of diabetes is characterised by increasing glucose levels requiring increasing therapy. | 270-387 | 270 | 387 | The natural progression of @OBJECT$ is @PREDICAT$ by increasing @SUBJECT$ levels requiring increasing therapy. |
Probable | preserve | 955-965 | 955-965 | T63 | management | TREATS | 955 | 965 | preserve | 921-928 | 921-928 | T58 | insulin | AminoAcidPeptideOrProtein | 921 | 928 | preserve | 975-990 | 982-990 | T62 | type 2 diabetes | DiseaseOrSyndrome | 975 | 990 | A5 | It now appears that insulin has a role earlier in the management of type 2 diabetes. | 901-991 | 901 | 991 | It now appears that @SUBJECT$ has a role earlier in the @PREDICAT$ of @OBJECT$ . |
Fact | preserve | 1508-1512 | 1508-1512 | T101 | with | PROCESS_OF | 1,508 | 1,512 | preserve | 1513-1520 | 1513-1520 | T97 | obesity | DiseaseOrSyndrome | 1,513 | 1,520 | preserve | 1496-1507 | 1496-1507 | T96 | individuals | Human | 1,496 | 1,507 | A1 | Expression of UCP2 mRNA in subcutaneous adipose tissue was similar in lean individuals and in individuals with obesity, and was increased by 58% during active weight loss. | 1396-1579 | 1,396 | 1,579 | Expression of UCP2 mRNA in subcutaneous adipose tissue was similar in lean individuals and in @OBJECT$ @PREDICAT$ @SUBJECT$ , and was increased by 58% during active weight loss. |
Fact | preserve | 1159-1161 | 1159-1161 | T82 | in | LOCATION_OF | 1,159 | 1,161 | preserve | 1162-1177 | 1171-1177 | T77 | skeletal muscle | Tissue | 1,162 | 1,177 | preserve | 1120-1124 | 1120-1124 | T74 | UCP2 | GeneOrGenome | 1,120 | 1,124 | A2 | In contrast, UCP2 mRNA levels were increased by 30% in skeletal muscle of 20% weight-reduced subjects with obesity. | 1107-1228 | 1,107 | 1,228 | In contrast, @OBJECT$ mRNA levels were increased by 30% @PREDICAT$ @SUBJECT$ of 20% weight-reduced subjects with obesity. |
Fact | preserve | 639-641 | 639-641 | T52 | in | LOCATION_OF | 639 | 641 | preserve | 665-692 | 686-692 | T46 | white adipose tissue | Tissue | 665 | 692 | preserve | 587-591 | 587-591 | T40 | UCP3 | GeneOrGenome | 587 | 591 | A3 | RESEARCH METHODS AND PROCEDURES: UCP2, UCP3 long and short mRNA levels were examined in skeletal muscle and in white adipose tissue of lean, obese, and weight-reduced individuals by RNase protection assay. | 548-766 | 548 | 766 | RESEARCH METHODS AND PROCEDURES: UCP2, @OBJECT$ long and short mRNA levels were examined @PREDICAT$ skeletal muscle and in @SUBJECT$ of lean, obese, and weight-reduced individuals by RNase protection assay. |
Fact | preserve | 1636-1638 | 1636-1638 | T111 | in | PROCESS_OF | 1,636 | 1,638 | preserve | 1624-1635 | 1629-1635 | T105 | body weight | OrganismAttribute | 1,624 | 1,635 | preserve | 1639-1645 | 1639-1645 | T106 | humans | Human | 1,639 | 1,645 | A4 | DISCUSSION: Stabilization at reduced body weight in humans is associated with a decrease in UCP3 mRNA in muscle. | 1580-1705 | 1,580 | 1,705 | DISCUSSION: Stabilization at reduced @SUBJECT$ @PREDICAT$ @OBJECT$ is associated with a decrease in UCP3 mRNA in muscle. |
Fact | preserve | 639-641 | 639-641 | T52 | in | LOCATION_OF | 639 | 641 | preserve | 642-657 | 651-657 | T45 | skeletal muscle | Tissue | 642 | 657 | preserve | 587-591 | 587-591 | T40 | UCP3 | GeneOrGenome | 587 | 591 | A9 | RESEARCH METHODS AND PROCEDURES: UCP2, UCP3 long and short mRNA levels were examined in skeletal muscle and in white adipose tissue of lean, obese, and weight-reduced individuals by RNase protection assay. | 548-766 | 548 | 766 | RESEARCH METHODS AND PROCEDURES: UCP2, @OBJECT$ long and short mRNA levels were examined @PREDICAT$ @SUBJECT$ and in white adipose tissue of lean, obese, and weight-reduced individuals by RNase protection assay. |
Uncommitted | preserve | 497-507 | 497-507 | T35 | associated | ASSOCIATED_WITH | 497 | 507 | preserve | 467-471 | 467-471 | T29 | UCP2 | GeneOrGenome | 467 | 471 | preserve | 519-526 | 519-526 | T33 | obesity | DiseaseOrSyndrome | 519 | 526 | A10 | In this paper, we investigated whether altered UCP2 and UCP3 mRNA levels are associated with obesity or weight reduction. | 414-547 | 414 | 547 | In this paper, we investigated whether altered @SUBJECT$ and UCP3 mRNA levels are @PREDICAT$ with @OBJECT$ or weight reduction. |
Fact | preserve | 1805-1807 | 1805-1807 | T123 | in | PROCESS_OF | 1,805 | 1,807 | preserve | 1786-1804 | 1793-1804 | T118 | energy expenditure | PhysiologicFunction | 1,786 | 1,804 | preserve | 1838-1849 | 1838-1849 | T121 | individuals | Human | 1,838 | 1,849 | A12 | It is possible that reduced UCP3 expression could contribute to decreased energy expenditure in weight-stable, weight-reduced individuals. | 1706-1850 | 1,706 | 1,850 | It is possible that reduced UCP3 expression could contribute to decreased @SUBJECT$ @PREDICAT$ weight-stable, weight-reduced @OBJECT$ . |
Fact | preserve | 1070-1074 | 1070-1074 | T73 | with | PROCESS_OF | 1,070 | 1,074 | preserve | 1075-1082 | 1075-1082 | T71 | obesity | DiseaseOrSyndrome | 1,075 | 1,082 | preserve | 1061-1069 | 1061-1069 | T70 | patients | PatientOrDisabledGroup | 1,061 | 1,069 | A13 | In contrast, UCP3L and UCP3S mRNAs were decreased by 38% (p<0.0059) and 48% (p<0.0047), respectively, in 20% weight-reduced patients with obesity at stable weight. | 925-1106 | 925 | 1,106 | In contrast, UCP3L and UCP3S mRNAs were decreased by 38% (p<0.0059) and 48% (p<0.0047), respectively, in 20% weight-reduced @OBJECT$ @PREDICAT$ @SUBJECT$ at stable weight. |
Fact | preserve | 1396-1406 | 1396-1406 | T100 | Expression | PART_OF | 1,396 | 1,406 | preserve | 1410-1414 | 1410-1414 | T91 | UCP2 | GeneOrGenome | 1,410 | 1,414 | preserve | 1423-1456 | 1450-1456 | T93 | subcutaneous adipose tissue | Tissue | 1,423 | 1,456 | A15 | Expression of UCP2 mRNA in subcutaneous adipose tissue was similar in lean individuals and in individuals with obesity, and was increased by 58% during active weight loss. | 1396-1579 | 1,396 | 1,579 | @PREDICAT$ of @SUBJECT$ mRNA in @OBJECT$ was similar in lean individuals and in individuals with obesity, and was increased by 58% during active weight loss. |
Fact | preserve | 313-322 | 313-322 | T24 | expressed | PART_OF | 313 | 322 | preserve | 305-309 | 305-309 | T22 | UCP3 | GeneOrGenome | 305 | 309 | preserve | 343-358 | 352-358 | T23 | skeletal muscle | Tissue | 343 | 358 | A16 | UCP2 is expressed widely, and UCP3 is expressed abundantly in skeletal muscle. | 275-359 | 275 | 359 | UCP2 is expressed widely, and @SUBJECT$ is @PREDICAT$ abundantly in @OBJECT$ . |
Fact | preserve | 894-898 | 894-898 | T65 | with | PROCESS_OF | 894 | 898 | preserve | 899-906 | 899-906 | T62 | obesity | DiseaseOrSyndrome | 899 | 906 | preserve | 882-893 | 882-893 | T61 | individuals | Human | 882 | 893 | A17 | RESULTS: Expression of UCP2, UCP3S, and UCP3L mRNA in skeletal muscle was similar in lean individuals and in individuals with obesity at stable weight. | 767-924 | 767 | 924 | RESULTS: Expression of UCP2, UCP3S, and UCP3L mRNA in skeletal muscle was similar in lean individuals and in @OBJECT$ @PREDICAT$ @SUBJECT$ at stable weight. |
Uncommitted | preserve | 497-507 | 497-507 | T35 | associated | ASSOCIATED_WITH | 497 | 507 | preserve | 476-480 | 476-480 | T30 | UCP3 | GeneOrGenome | 476 | 480 | preserve | 519-526 | 519-526 | T33 | obesity | DiseaseOrSyndrome | 519 | 526 | A18 | In this paper, we investigated whether altered UCP2 and UCP3 mRNA levels are associated with obesity or weight reduction. | 414-547 | 414 | 547 | In this paper, we investigated whether altered UCP2 and @SUBJECT$ mRNA levels are @PREDICAT$ with @OBJECT$ or weight reduction. |
Doubtful | preserve | 1756-1766 | 1756-1766 | T122 | contribute | AFFECTS | 1,756 | 1,766 | preserve | 1734-1738 | 1734-1738 | T115 | UCP3 | GeneOrGenome | 1,734 | 1,738 | preserve | 1786-1804 | 1793-1804 | T118 | energy expenditure | PhysiologicFunction | 1,786 | 1,804 | A19 | It is possible that reduced UCP3 expression could contribute to decreased energy expenditure in weight-stable, weight-reduced individuals. | 1706-1850 | 1,706 | 1,850 | It is possible that reduced @SUBJECT$ expression could @PREDICAT$ to decreased @OBJECT$ in weight-stable, weight-reduced individuals. |
Fact | preserve | 1549-1569 | 1557-1569 | T95 | inverse relationship | ISA | 1,549 | 1,569 | preserve | 1549-1556 | 1549-1556 | T87 | inverse | QualitativeConcept | 1,549 | 1,556 | preserve | 1557-1569 | 1557-1569 | T88 | relationship | QualitativeConcept | 1,557 | 1,569 | A3 | In symptomatic patients there was a significant inverse relationship between the number of ES per hour and time elapsed since last symptoms (Spearman's rho=-0.2558, P=0.034). | 1495-1681 | 1,495 | 1,681 | In symptomatic patients there was a significant @SUBJECT$ @PREDICAT$ @OBJECT$ between the number of ES per hour and time elapsed since last symptoms (Spearman's rho=-0.2558, P=0.034). |
Fact | preserve | 2012-2033 | 2025-2033 | T115 | asymptomatic patients | PROCESS_OF | 2,012 | 2,033 | preserve | 2012-2024 | 2012-2024 | T113 | asymptomatic | Finding | 2,012 | 2,024 | preserve | 2025-2033 | 2025-2033 | T114 | patients | PatientOrDisabledGroup | 2,025 | 2,033 | A4 | The presence of ES at entry was predictive of TIA and stroke risk during follow up in both symptomatic (P=0.02) and asymptomatic patients (P=0.007). | 1890-2050 | 1,890 | 2,050 | The presence of ES at entry was predictive of TIA and stroke risk during follow up in both symptomatic (P=0.02) and @SUBJECT$ @PREDICAT$ @OBJECT$ (P=0.007). |